|
Nuvo Provides Update On Long-Term Safety Trial For Pennsaid® |
|
|
|
02 Mar 2006 |
MARKHAM, Canada | Mar 01, 2006 | Nuvo Research Inc. (TSX:NRI) today announced it has completed an initial analysis of the data in its Phase III long-term, openlabel safety trial (“Study 112E”) for Pennsaid®. A full review of the data is currently underway.
“An initial analysis of the results has been completed and confirms the safety profile of Pennsaid® reported in the previous multiple short-term trials. The full analysis of data from this trial is still underway and we anticipate will be completed in the next 4-6 weeks,” said Dr. Henrich Guntermann, Nuvo’s President and CEO. “The results of this study will form part of our NDA submission for Pennsaid®, which remains on schedule for mid 2006.” The trial involved more than 300 patients who were administered Pennsaid® for 26 weeks and a subset of more than 100 of these patients who were administered the drug for a total of 52 weeks. Pennsaid® is a topical non-steroidal anti-inflammatory (NSAID) used for the treatment of osteoarthritis and is currently approved for sale in Canada and several European countries.
About Nuvo Research Inc.
Nuvo is focused on developing innovative site-specific therapeutics that are delivered topically using the Company’s skin-penetrating technologies. Nuvo’s lead product is Pennsaid®, a topical non-steroidal anti-inflammatory (NSAID) used for the treatment of osteoarthritis. Nuvo intends to leverage its skin-penetrating technologies to create a portfolio of transdermal products targeting a variety of indications. Nuvo Research Inc. is a publicly traded, Canadian pharmaceutical company headquartered in Markham, Ontario, with manufacturing facilities in Varennes, Québec and Wanzleben, Germany. For more information, please visit www.nuvoresearch.com.
SOURCE: Nuvo Research, Inc |
